Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE versus RIOMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE versus RIOMET.
GLUCOPHAGE vs RIOMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production (gluconeogenesis) and increases peripheral insulin sensitivity, reducing glucose absorption from the gastrointestinal tract. It activates AMP-activated protein kinase (AMPK), leading to inhibition of gluconeogenic enzymes.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day divided twice daily; extended-release: 500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day once daily.
Oral, 500 mg twice daily or 850 mg once daily, increased gradually to 2000 mg daily in divided doses.
None Documented
None Documented
Terminal elimination half-life: 6.2 hours (range 4.0-8.7 h); prolonged in renal impairment (up to 17.6 h at CrCl <60 mL/min).
Terminal elimination half-life: 6.2 hours (range 4–12 hours); clinical context: 4–5 half-lives to steady state (approx 24–36 hours); prolonged in renal impairment (e.g., creatinine clearance <60 mL/min contraindicated)
Renal elimination of unchanged drug: 90%; fecal: 10% (biliary negligible).
Renal (90% unchanged via glomerular filtration and tubular secretion); fecal (10%)
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic